Profile data is unavailable for this security.
About the company
Terragen Holdings Limited is an agricultural biological company. The Company is specializing in the application of microbial technology. The Company conducts research activities for the advancement of the use of probiotics in agricultural applications. Research is focused on determining the optimum combination and concentration of naturally occurring live microbe strains to help boost the productivity, welfare and resilience of farm production animals and address soil health. The Company has two products on the market in Australia and New Zealand: a microbial feed supplement for animals known as Mylo, and a soil conditioner called Great Land Plus. Mylo is an easy-to-use liquid feed supplement for dairy calves and cows that contains a specialized selection and blend of live microbes. Great Land Plus helps farmers enhance soil characteristics, making nutrients more available to plants. It may also improve yield by changing the soil microbiome and enhancing root development.
- Revenue in AUD (TTM)2.60m
- Net income in AUD-2.53m
- Incorporated1996
- Employees--
- LocationTerragen Holdings LtdUnit 6, 41 Access Crescent,COOLUM BEACH 4573AustraliaAUS
- Phone+61 30083-7724
- Websitehttps://www.terragen.com.au/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hydration Pharmaceuticals Co Ltd | 15.09m | -12.18m | 2.74m | -- | -- | -- | -- | 0.1819 | -0.0625 | -0.0625 | 0.0773 | -0.002 | 1.18 | 1.61 | 6.60 | -- | -94.86 | -79.98 | -143.75 | -111.57 | 53.70 | 48.73 | -80.69 | -99.53 | 1.37 | -21.48 | 1.10 | -- | 10.34 | 19.27 | 23.61 | -- | -- | -- |
| Cambium Bio Ltd | -28.22k | -366.01k | 3.83m | -- | -- | -- | -- | -- | -0.0012 | -0.0012 | -0.00009 | -0.0036 | -0.039 | -- | -- | -- | -50.58 | -49.44 | -- | -292.47 | -- | -- | -- | -118.34 | -- | -- | -- | -- | -- | -- | 60.86 | -- | -- | -- |
| Terragen Holdings Ltd | 2.60m | -2.53m | 4.06m | -- | -- | 0.5939 | -- | 1.56 | -0.0099 | -0.0099 | 0.0101 | 0.0185 | 0.3364 | 0.5758 | 11.93 | -- | -32.71 | -43.86 | -39.59 | -50.11 | 96.61 | 87.96 | -97.24 | -173.81 | 5.79 | -347.50 | 0.0587 | -- | 13.67 | 31.22 | 40.19 | -- | -12.30 | -- |
| Zelira Therapeutics Ltd | 1.62m | -36.43m | 4.20m | 8.00 | -- | -- | -- | 2.59 | -3.23 | -3.23 | 0.148 | -0.2063 | 0.0848 | 0.185 | 3.55 | -- | -193.14 | -27.71 | -243.04 | -28.81 | 82.28 | -- | -2,278.17 | -508.48 | 0.1488 | -22.80 | -- | -- | -80.95 | -0.3635 | 53.35 | -- | -- | -- |
| Bod Science Ltd | 3.32m | -7.95m | 4.26m | -- | -- | -- | -- | 1.28 | -0.0557 | -0.0557 | 0.0235 | -0.0046 | 0.7533 | 2.42 | 8.05 | -- | -180.40 | -94.62 | -465.66 | -145.77 | 69.23 | 47.08 | -239.47 | -129.48 | 0.8319 | -- | 3.71 | -- | -34.70 | 23.20 | -47.10 | -- | 8.23 | -- |
| Vectus Biosystems Ltd | 86.39k | -2.49m | 4.26m | -- | -- | 1.80 | -- | 49.27 | -0.0467 | -0.0467 | 0.0016 | 0.0445 | 0.0191 | -- | -- | -- | -54.95 | -96.22 | -68.14 | -691.17 | -- | -- | -2,880.80 | -27,693.78 | -- | -439.76 | 0.00 | -- | 69,287.50 | 97.87 | 13.64 | -- | -- | -- |
| Invex Therapeutics Ltd | 837.95k | -6.01m | 5.56m | -- | -- | 1.05 | -- | 6.64 | -0.08 | -0.08 | 0.0112 | 0.0705 | 0.0521 | -- | 2.79 | -- | -37.38 | -- | -40.06 | -- | -- | -- | -717.76 | -- | -- | -- | 0.00 | -- | 379.22 | -- | -96.04 | -- | -- | -- |
| Neuroscientific Biopharmaceuticals Ltd | 3.94m | 761.17k | 5.64m | -- | 7.22 | 1.48 | 6.78 | 1.43 | 0.0054 | 0.0054 | 0.0273 | 0.0264 | 1.02 | -- | 76.13 | -- | 19.64 | -55.72 | 23.29 | -60.89 | -- | -- | 19.34 | -301.54 | -- | 54.64 | 0.00 | -- | 7,292.97 | 179.97 | 89.76 | -- | -- | -- |
